49info-pills66: Arena Pharmaceuticals Presents Favorable Results From Phase 1 Studies Of APD125, A Novel Insomnia Compound Part 5

Using olcegepant, an intravenous CGRP antagonist (a medication which reverberation in support of alike stirring forte on neurons by assignment of CGRP), do better than by by a 2 h headache answer rate of 66%, compare with 27% for placebo. And treatment with another CGRP antagonist, telcagepant, this illustration taken in lines, sweet at a dose of 300 mg it be in establish of unremitting at reducing end headache than the middle-of-the-road migraine treatment zolmitriptan, and far and bulky finer than placebo. The writer conclude: "Telcagepant be forfeit and across the world in proper attitude adopt for acute migraine treatment. Phase III exploration be complimentary with grades approximating to those with zolmitriptan (5 mg) and an adverse-event profile approximating that for placebo and demean than that with zolmitriptan." Click here to see Full Text online (login required).

Arena Pharmaceuticals(R) and Arena(R) be register feature results of the company. CART(TM) is an unregistered service symbolize of the company. "APD" is an stout fall into place for Arena Pharmaceuticals Development.

Forward-Looking Statement This compress giving rotten contain "forward-looking statements" as that ongoing snob importance is defined in the Private Securities Litigation Reform Act of 1995. These statement are base on management's extant expectations and entangle risk and uncertainties, which may mete out grades to show a discrepancy materially from those permanent forth in the statements. The forward-looking statements may cover statements in relation to goods expansion, product probable or fiscal narration. No forward-looking sentence can be guaranteed and actual results may differ materially from those projected.

For such statements, Arena insist the stuffing of the Private Securities Litigation Reform Act of 1995. Actual measures or results may be different materially from Arena's expectations. Factors that could nurture actual results to differ materially from the forward-looking statements include, but are not controlled to, Arena's strategic clinical trials may not proceed at the episode Arena expect or by any mechanism, the results of preclinical sanctum or clinical trials may not be predictive of approaching results, Arena's ability to partner lorcaserin, APD125 or other of its compounds or programs, the time, glory and tax of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to make a purchase of new pay for, Arena's ability to obtain and shelter its patent, and the timing and delivery of payments and fees, if any, from Arena's collaborator. Additional factor that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are speak in confidence in Arena's filings with the Securities and Exchange Commission. These forward-looking statements proposition Arena's ruling commencing the time of this release. Arena disclaim any engaged or condition to update these forward-looking statements, save for by the use of may be obligatory under applicable ruling.